Data / Drug companies / Nelarabine
Nelarabine: 13 companies and 15 products in the FDA NDC directory
Nelarabine is listed in the FDA National Drug Code Directory by 13 companies, with 15 products in commercial distribution. 14 of the products (93.3%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are injection; injection, solution, and the newest product started marketing on August 31, 2025.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 13
- Products
- 15
- Generic (ANDA) products
- 14 (93.3%)
- Application numbers
- 10
- Routes
- Intravenous
- Brand names
- Arranon
- openFDA record search
- api.fda.gov
Companies that list nelarabine
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Shorla Oncology Inc. | 2 | injection | Generic drugs (ANDA) | August 31, 2025 |
| Zydus Pharmaceuticals USA Inc. | 2 | injection | Generic drugs (ANDA) | June 24, 2022 |
| Alembic Pharmaceuticals Inc. | 1 | injection | Generic drugs (ANDA) | August 1, 2024 |
| Alembic Pharmaceuticals Limited | 1 | injection | Generic drugs (ANDA) | August 1, 2024 |
| Amneal Pharmaceuticals LLC | 1 | injection | Generic drugs (ANDA) | April 10, 2023 |
| Dr. Reddy's Laboratories Inc. | 1 | injection | Generic drugs (ANDA) | January 9, 2023 |
| Gland Pharma Limited | 1 | injection | Generic drugs (ANDA) | January 3, 2024 |
| Meitheal Pharmaceuticals Inc. | 1 | injection | Generic drugs (ANDA) | January 10, 2023 |
| Novadoz Pharmaceuticals LLC | 1 | injection | Generic drugs (ANDA) | September 13, 2024 |
| Sagent Pharmaceuticals | 1 | injection, solution | Generic drugs (ANDA) | August 1, 2024 |
| Sandoz Inc | 1 | injection | New drug applications (NDA) | October 5, 2016 |
| XGen Pharmaceuticals DJB, Inc. | 1 | injection | Generic drugs (ANDA) | February 17, 2025 |
| Zydus Lifesciences Limited | 1 | injection | Generic drugs (ANDA) | November 17, 2021 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection | 14 | 93.3% |
| Injection, solution | 1 | 6.7% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 14 | 93.3% |
| New drug applications (NDA) | 1 | 6.7% |
Pharmacologic classes
| Class | Products |
|---|---|
| Nucleoside Metabolic Inhibitor | 15 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.